Furthermore, and consistent with an important role for mTOR-driven inflammatory T cells in the pathogenesis of lupus, a recent phase 1/2 trial reported that rapamycin had a beneficial impact on clinical disease scores in a cohort of 43 SLE patients (Lai et al., 2018). The gene discussed is MTOR; the disease is systemic lupus erythematosus.